Lataa...
Results of clinical trials with anti-programmed death 1/programmed death ligand 1 inhibitors in lung cancer
One of the main hallmarks of cancer is the capability of evading immune destruction. In order to drive tumor progression, malignant cells are able to promote immunosuppressive mechanisms avoiding recognition and elimination. Increasing knowledge of the mechanisms of immune tolerance has led to the i...
Tallennettuna:
| Julkaisussa: | Transl Lung Cancer Res |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
AME Publishing Company
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4700219/ https://ncbi.nlm.nih.gov/pubmed/26798585 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2015.12.06 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|